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Macrophages infiltrate hypoxic tumor regions, where they promote angiogenesis and immunosuppression.
In this issue of Cancer Cell, Casazza and colleagues report that tumor-associated macrophage (TAM) entry
into avascular tumor areas is regulated by Semaphorin 3A/Neuropilin-1 signaling; interference with this
pathway entraps TAMs in oxygenated areas, preventing their tumorigenic function.Tumor-associated macrophages (TAMs)
are tissue-resident cells that differentiate
from circulating monocytes in peripheral
blood. They can constitute the major
leukocytic infiltrate found within the
stroma of many tumor types. Although
macrophages in normal tissues are impli-
cated in phagocytosis of microbes and
antigen presentation to T cells, TAMs
have two opposing phenotypes; they
can either endorse proimmune and tu-
moricidal processes or promote tumor
growth and metastasis by suppressing
immunity and promoting angiogenesis.
The phenotype of TAMs is regulated by
specific tumor-derived chemokines and
cytokines that polarize macrophages
to a proimmune ‘‘M1’’ or immunesuppres-
sive/proangiogenic ‘‘M2’’ phenotype. The
dichotomous TAM phenotypes may
explain why TAMs can elicit a poor prog-
nosis in some tumors, including glioma
and breast cancers, and a better prog-
nosis in others, such as stomach and co-
lon cancers and some prostate and non-
small cell lung cancers (Allavena et al.,
2008; Bingle et al., 2002). Macrophage
polarization is also, in part, regulated by
intratumoral hypoxia, in which infiltrating
myeloid cells accumulate and are stimu-
lated to secrete various immune suppres-
sive and proangiogenic factors (De Palma
and Lewis, 2013; Qian and Pollard, 2010).
In this issue of Cancer Cell, Casazza
et al. (2013) describe a Neuropilin-1
(Nrp1)-dependent guidance mechanism
by which macrophages enter hypoxic
areas to elicit proangiogenic and immune
suppressive functions (Figure 1). Utilizing
elegant genetic tools to interfere withNrp1 function in TAMs in various mouse
tumor models, they demonstrated that
Semaphorin3A (Sema3A) mediates Nrp-
1-dependent signaling of a PlexinA1/
PlexinA4/VEGFR1 holoreceptor complex
that leads to VEGFR1 activation in TAMs
and their subsequent migration into hyp-
oxic regions. Notably, although Sema3A
and VEGF levels are both increased under
hypoxic conditions, Sema3A, but not
VEGF, was sufficient to attract TAMs.
They tested this by generating TAMs with
a Sema3A-binding mutant of Nrp1 that
was still able to bind to VEGF. Thesemac-
rophages failed to enter hypoxic regions
of the tumor similarly to Nrp1-KO TAMs.
As soon as TAMs were positioned in
the hypoxic environment, Nrp1 expres-
sion was repressed; this terminated the
migratory response of TAMs to Sema3A.
Interestingly, hypoxia-dependent Nrp1
repression was facilitated by HIF2a-medi-
ated activation of the NF-kBpathway. The
loss of Nrp1 switched Sema3A to medi-
ating a PlexinA1/PlexinA4-mediated TAM
arrest antagonizing VEGFR1-induced
attraction and entrapping TAMs in hypox-
ic regions (Figure 1). As TAMs shift from an
anti- to a protumoral phenotype upon as-
sociation with hypoxic environments, the
authors then asked how loss of Nrp1 in
TAMs and their subsequent differing posi-
tioning within tumors would affect tumor
propagation and progression.
Casazza et al. (2013) explored the func-
tion of Nrp1 on TAMs by creating condi-
tional TAM-specific Nrp1-knockout (KO)
mice. Orthotopic lung and pancreatic
tumors, and tumors from a transgenic
breast cancer mouse model, in Nrp1-KOCancer Cell 24,mice grew to only a fraction of the size
of tumors in wild-type (WT) mice. Nrp-1
deficiency in TAMs yielded tumors with
nearly double the number of TAMs, likely
due to increased tumor hypoxia. Surpris-
ingly, however, TAMs solely accumu-
lated within normoxic regions. Moreover,
despite the increase in TAMs, endstage
tumors exhibited reduced vessel density
and perfusion, suggesting that Nrp1-KO
TAMs were impaired in their angiogenic
functions compared to their WT counter-
parts. Indeed, isolated WT TAMs induced
more robust endothelial cell migration and
capillary formation compared to Nrp1-
KO TAMs. In addition, Nrp1-KO TAMs
secreted more nitric oxide, increased
T cell proliferation, and were more cyto-
toxic. Interestingly, Casazza et al. (2013)
found that the acquired ‘‘M1’’ TAM
phenotype was not endorsed by the lack
of Nrp1 per se, because WT and Nrp1-
KO macrophages obtained from bone
marrow were equally able to switch be-
tween proimmune and immune-suppres-
sive phenotypes upon appropriate stimu-
lation in vitro. Further, Nrp-1 deficiency in
TAMs neither affected the numbers of
circulating or resident monocyte numbers
nor changed proliferation and apoptosis
of macrophages precluding a Nrp1-
dependent regulation of monocyte/TAM
recruitment or differentiation. Rather,
these elegant studies revealed that block-
ing Nrp1 in TAMs was sufficient to keep
the cells in a tumor-suppressive state by
solely entrapping the cells in vascularized
normoxic tumor areas.
These studies support the concept
of macrophage ‘‘reprogramming’’ as aDecember 9, 2013 ª2013 Elsevier Inc. 687
Figure 1. Sema3A/Nrp1 Signaling Regulates TAM Entry into Hypoxic Regions and Thereby Promotes Tumor Progression
Intratumoral hypoxia enhances the expression of VEGF and Sema3A. Sema3A binds to the Nrp1/PlexinA1 (pA1)/PlexinA4 (pA4) holoreceptor complex at the TAM
surface, resulting in VEGFR1/Nrp1-dependent migration toward the Sema3A-expressing hypoxic area. Hypoxia-associated TAMs experience stabilization of
HIF2a, which induces expression of Ikbkb and Ikbkg, ultimately leading to phosphorylation of IkB and nuclear translocation of NF-kB. NF-kB then represses
expression of Nrp1. In the absence of Nrp1, Sema3A antagonizes migration signals through PlexinA1/PlexinA4 signaling, thus retaining and entrapping TAMs
within hypoxic areas. Here, TAMs are ‘‘educated’’ to endorse angiogenesis and suppress antitumor immunity, thus facilitating tumor progression. Sema3A/
PlexinA1/PlexinA4 retention signals entrap Nrp1-KO TAMs in normoxic areas by blocking VEGF-mediated migration into hypoxic regions. Nrp1-KO TAMs
therefore do not attain a tumor promoting phenotype and suppress tumor growth by stimulating antitumor immunity.
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gate angiogenesis and restore T cell-
mediated antitumor immunity (Coussens
et al., 2013). Further, Casazza et al.
(2013) provide a new therapeutic opportu-
nity to turn TAMs against cancer by
modulating their intratumoral location via
inhibition of Nrp1. Such an approach is
advantageous over those that target total
TAM infiltration as it harnesses the tumor
suppressing capacities of TAMs.
These studies also have important
clinical applications. Although histori-
cally successful tumor eradication had
been linked with tumor necrosis, various
studies have demonstrated that hypoxia-
generating drugs cause a more aggres-
sive disease, in part, by accumulating
more immune suppressive innate immune
cells that facilitate angiogenesis, tumor in-
vasion, and metastasis. Emerging data
support the notion that normalization of
the tumor vasculature provides beneficial688 Cancer Cell 24, December 9, 2013 ª201effects enabling better drug delivery and
an enhanced influx of T cells. A recent
study by Klug et al. (2013) demonstrated
that low-dose irradiation and T cell trans-
fer normalized the tumor vasculature
and enhanced the recruitment CD8+
T cells and TAMs expressing high levels
of the M1 marker iNOS. Similarly, Ca-
sazza et al. (2013) found that normoxia
enhanced secretion of nitric oxide by
TAMs and induced CD8+ T cell expan-
sion. Thus, oxygenation of the tumor
should also help to redirect macrophage
differentiation to facilitate antitumor im-
munity. In addition, targeting Nrp1 would
restrict the TAMs to oxygenated areas
even during hypoxia-inducing therapies
including standard chemotherapy and
radiation therapy.
The authors confirm that exposure of
TAMs to hypoxia is a requisite for their
acquisition of a tumor promoting pheno-
type; however, whether or not hypoxia3 Elsevier Inc.directly regulates M2 reprogramming is
unclear. A recent study by Laoui et al.
(2013) suggests hypoxia plays a support-
ive rather than a direct role in driving
M2 functions by TAMs. Using prolyly-4
hydroxylase 2-haplodeficient mice, this
group found that reduced tumor hypoxia
resulted in downregulated TAM expres-
sion of genes involved in glycolysis,
angiogenesis, and metastasis and not in
typical M2 markers including mannose
receptor and arginase. This suggests tar-
geting the Nrp1/Sema3A axis can syner-
gize with reprogramming approaches to
provide better TAM-mediated antitumor
responses.
In support of these hypotheses,
blockade of Nrp1 in preclinical tumor
models has been encouraging, suppress-
ing both angiogenesis and tumor growth,
and clinical trials are currently ongoing
(Pan et al., 2007). As Nrp1 is expressed
in a variety of cell types besides TAMs,
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cells, it will be pivotal to analyze whether
the mechanism proposed by this study
is still evident when Nrp1 activity is
broadly abrogated in murine tumor
models and human tumors. Whether
TAM location and activity is similarly regu-
lated in other hypoxia-generating pathol-
ogies also warrants further investigation.
For example, in a mouse model of cere-
bral stroke, microglia and macrophages
were found to undergo M2 polarization
immediately after ischemic insult, but
eventually underwent M1 polarization
induced by ischemic neurons (Huang
and Feng, 2013). The M2 polarized cells
were found to have a protective effect
on neurons, whereas M1 polarized cells
promoted neuronal destruction; there-
fore, preventing microglia and macro-phages from associating with ischemic
areas might maintain their neuronal-pro-
tective phenotypes. If validated, manipu-
lation of the Nrp1/Sema3A axis could
become a valuable agent for diseases
like ischemia and stroke to redirect
macrophage function and improve patient
outcome.REFERENCES
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The 5-year survival for localized rhabdomyosarcoma is over 70%, but only 30% for patients presenting with
metastatic disease. In this issue of Cancer Cell, Chen and colleagues performed whole-genome and RNA
sequencing on human rhabdomyosarcoma and identified RAS mutations and oxidative stress as potential
therapeutic targets for high-risk embryonal rhabdomyosarcoma.Rhabdomyosarcoma (RMS) is the most
commonly diagnosed soft tissue sarcoma
in children. The two major subtypes, alve-
olar (ARMS) and embryonal (ERMS), differ
in their histological features, genetic
mutations, age of onset, and prognosis
(Parham and Ellison, 2006). ERMS, more
commonly diagnosed in children less
than 10 years of age, is characterized
by the presence of rhabdomyoblasts,
cells with eccentric nuclei and eosino-
philic cytoplasm, embedded in a myxoid
stroma. ARMS, more commonly diag-
nosed in children over 10 years of age, is
distinguished histologically by clusters of
small, round, blue cells in a highly cellularbackground. Most tumors with ARMS
histology have chromosomal transloca-
tions t(2;13)(q35;q14) or t(1;13)(p36;q14),
resulting in the expression of either
PAX3-FOXO1 or PAX7-FOXO1 fusion
proteins, with few other chromosomal
alterations. In contrast, ERMS frequently
possesses multiple chromosomal alter-
ations. Although most cases of RMS
occur sporadically, inherited syndromes
with germline mutations associated with
developing RMS include Neurofibroma-
tosis Type I (NF1) (Ferrari et al., 2007), Li-
Fraumeni (TP53) (Diller et al., 1995), Cost-
ello (HRAS) (Kratz et al., 2011), Noonan
(PTPN11, SOS1, RAF1, KRAS, NRAS,and BRAF) (Kratz et al., 2011), and Gorlin
syndromes (PTCH1) (Gorlin, 1987).
The current clinical criteria for classifi-
cation of RMS into low-, intermediate-,
or high-risk groups depend on primary
tumor site, size, surgical resectability,
and metastasis to regional lymph nodes
or distant sites (Malempati and Hawkins,
2012). Whereas the high-risk group en-
compasses metastatic RMS of both alve-
olar and embryonal subtypes regardless
of primary tumor size or site, ARMS
patients generally have worse clinical
outcomes than ERMS patients. Impor-
tantly, ARMS that is diagnosed at the his-
tological level and lacking PAX3-FOXO1December 9, 2013 ª2013 Elsevier Inc. 689
